Rebecca Ehrenkranz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rebecca Ehrenkranz has a total of 875 co-authors. Here are the top co-authors by number of shared publications:
- David Bryce Yaden
Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States of America
5 shared publications Xiaonan Zhu
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA
4 shared publicationsAbdulhalik Workicho
3 shared publications- Abdullah Tawfih Abdullah Khoja
Public Health and Family Medicine Departments, College of Medicine, Al-Imam Muhammad ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
3 shared publications - Aleksandra Barac
Emerging Infections Subcommittee, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3 shared publications Amir Kasaeian
3 shared publications
Latest Publications
- Open Access
An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or pharmacotherapy. Design: Waitlist-controlled open label randomized clinical trial. Setting: Data were collected at the Johns Hopkins University School of Medicine. Participants: Data were analyzed from 30 participants (total randomized N=37, by age, sex and OCD severity) with a failed previous attempt at either pharmacotherapy or evidence-based psychotherapies such as exposure response prevention (ERP). Intervention: Participants received two psilocybin doses over two weeks (20 mg followed by 30 mg, if well-tolerated) under supportive conditions. The immediate-treatment arm received the drug within a month following enrollment, and the waitlist-control arm received identical support and dosing after an 8-week waiting period. Main Outcome: Clinician-administered Y-BOCS scores was collected one week post each drug administration and one month post session 2. Self-assessed reports were collected for acute subjective effects (Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), and 11-Dimensional Altered States of Consciousness (11D-ASC)), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: A total of 37 participants were enrolled in the study (age: 38.4±11.6 years; 21 [56.75%] female), with 30 [81.08%] completing the 1-month follow-up. We show that two successive doses of psilocybin over two weeks were well-tolerated, leading to reduction in OCD symptoms. Compared with the waitlist group (N=14), the immediate-treatment group (N=16) showed a reduction in the Y-BOCS scores (F(2,56)=16.17, p2 □=0.37) post session. This improvement persisted one month after the second psilocybin dose for both groups post treatment crossover for waitlisted group (F(3,84)=29.91, p2 □=0.52). Y-BOCS scores were correlated with several acute subjective effects measures, including total scores on MEQ, and individual factors on CEQ and 11D-ASC. Conclusions and Relevance: Repeated psilocybin administration is tolerable and potentially efficacious in reducing OCD symptoms. These results support further investigation of multi dose psilocybin protocols as a viable therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier NCT05546658 Key points: Psilocybin was generally safe and tolerated across repeated dosing Psilocybin produced reductions in OCD symptom severity Quality of the psychedelic experience was correlated with therapeutic benefit
Open AccessAn Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or pharmacotherapy. Design: Waitlist-controlled open label randomized clinical trial. Setting: Data were collected at the Johns Hopkins University School of Medicine. Participants: Data were analyzed from 30 participants (total randomized N=37, by age, sex and OCD severity) with a failed previous attempt at either pharmacotherapy or evidence-based psychotherapies such as exposure response prevention (ERP). Intervention: Participants received two psilocybin doses over two weeks (20 mg followed by 30 mg, if well-tolerated) under supportive conditions. The immediate-treatment arm received the drug within a month following enrollment, and the waitlist-control arm received identical support and dosing after an 8-week waiting period. Main Outcome: Clinician-administered Y-BOCS scores was collected one week post each drug administration and one month post session 2. Self-assessed reports were collected for acute subjective effects (Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), and 11-Dimensional Altered States of Consciousness (11D-ASC)), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: A total of 37 participants were enrolled in the study (age: 38.4±11.6 years; 21 [56.75%] female), with 30 [81.08%] completing the 1-month follow-up. We show that two successive doses of psilocybin over two weeks were well-tolerated, leading to reduction in OCD symptoms. Compared with the waitlist group (N=14), the immediate-treatment group (N=16) showed a reduction in the Y-BOCS scores (F(2,56)=16.17, p2 □=0.37) post session. This improvement persisted one month after the second psilocybin dose for both groups post treatment crossover for waitlisted group (F(3,84)=29.91, p2 □=0.52). Y-BOCS scores were correlated with several acute subjective effects measures, including total scores on MEQ, and individual factors on CEQ and 11D-ASC. Conclusions and Relevance: Repeated psilocybin administration is tolerable and potentially efficacious in reducing OCD symptoms. These results support further investigation of multi dose psilocybin protocols as a viable therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier NCT05546658 Key points: Psilocybin was generally safe and tolerated across repeated dosing Psilocybin produced reductions in OCD symptom severity Quality of the psychedelic experience was correlated with therapeutic benefit
- 18 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1862-1876
Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Background: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden. Aims: Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF). Methods: Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals. Results: We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning. Conclusions: We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.
- 18 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1862-1876
Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Background: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden. Aims: Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF). Methods: Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals. Results: We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning. Conclusions: We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.
- 14 January 2026
- Published by Taylor & Francis in Accountability in Research
- Vol. 33 (4) , 2601225
Analyzing the concept of independence in psychedelic research
A number of proposals across different fields have suggested incorporating "independent" actors into the research process as a way to manage potential bias. For example, in response to allegations of bias in psychedelic science, some have suggested the idea of independent auditors for adverse events, as well as the incorporation of independent researchers into the research teams of psychedelic trials. However, despite growing interest in these methods, the concept of independence itself remains frequently undefined. Moreover, although introducing independent actors may seem like a prima facie beneficial solution to help reduce bias and improve the scientific rigor of research, it may come with significant drawbacks as well. Here, we argue that the sense of independence on which these proposals for independent actors implicitly rely on is freedom from any influence that might alter the actors' choices in a way that reduces the trustworthiness or accuracy of research findings. Whether it is possible to identify and involve such actors without incurring trade-offs with other scientific desiderata (e.g. due to the risk of inadequate expertise) is then further explored. We conclude by providing two models in law and science that may be helpful to draw upon if seeking to incorporate independent actors.
- 14 January 2026
- Published by Taylor & Francis in Accountability in Research
- Vol. 33 (4) , 2601225
Analyzing the concept of independence in psychedelic research
A number of proposals across different fields have suggested incorporating "independent" actors into the research process as a way to manage potential bias. For example, in response to allegations of bias in psychedelic science, some have suggested the idea of independent auditors for adverse events, as well as the incorporation of independent researchers into the research teams of psychedelic trials. However, despite growing interest in these methods, the concept of independence itself remains frequently undefined. Moreover, although introducing independent actors may seem like a prima facie beneficial solution to help reduce bias and improve the scientific rigor of research, it may come with significant drawbacks as well. Here, we argue that the sense of independence on which these proposals for independent actors implicitly rely on is freedom from any influence that might alter the actors' choices in a way that reduces the trustworthiness or accuracy of research findings. Whether it is possible to identify and involve such actors without incurring trade-offs with other scientific desiderata (e.g. due to the risk of inadequate expertise) is then further explored. We conclude by providing two models in law and science that may be helpful to draw upon if seeking to incorporate independent actors.
- 3 April 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 380, 561-575
The efficacy of psychotherapeutic interventions for prolonged grief disorder: A systematic review
- 3 April 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 380, 561-575
The efficacy of psychotherapeutic interventions for prolonged grief disorder: A systematic review
- Open Access
- 2 April 2025
- Published by SAGE Publications in Research Ethics
- Vol. 22 (1) , 57-80
Enhanced independence: De-biasing processes in psychedelic research and beyond
Randomized controlled trials (RCTs) are considered the gold standard for demonstrating the efficacy of a treatment or intervention; however, the RCT study design alone is insufficient to prevent all forms of bias. In this paper, we review conflicts of interest and other biases that pose challenges to the methodological rigor of psychedelic RCTs, and explore recommended bias mitigation measures. We focus on biases of special relevance to psychedelic RCTs and methods of mitigating bias that we believe are actionable and urgent practices to implement in psychedelic research: (1) independent data assessment, (2) multisite trials, (3) quantitative bias analysis, and (4) open science practices. Although we advocate for the adoption of these practices in psychedelic research, they are not psychedelic specific. We suggest that the challenges posed by psychedelic research offer an opportunity for researchers to creatively find and implement solutions across the study lifecycle to reduce bias in other fields of clinical research.
- 2 April 2025
- Published by SAGE Publications in Research Ethics
- Vol. 22 (1) , 57-80
Open AccessEnhanced independence: De-biasing processes in psychedelic research and beyond
Randomized controlled trials (RCTs) are considered the gold standard for demonstrating the efficacy of a treatment or intervention; however, the RCT study design alone is insufficient to prevent all forms of bias. In this paper, we review conflicts of interest and other biases that pose challenges to the methodological rigor of psychedelic RCTs, and explore recommended bias mitigation measures. We focus on biases of special relevance to psychedelic RCTs and methods of mitigating bias that we believe are actionable and urgent practices to implement in psychedelic research: (1) independent data assessment, (2) multisite trials, (3) quantitative bias analysis, and (4) open science practices. Although we advocate for the adoption of these practices in psychedelic research, they are not psychedelic specific. We suggest that the challenges posed by psychedelic research offer an opportunity for researchers to creatively find and implement solutions across the study lifecycle to reduce bias in other fields of clinical research.
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 59-62
Adverse Events Should Not Be Surprising in Psychedelic Research
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics within the scientific community and broader public. Coverage of psychedelic science has swung between a pendulum of extremes, from fearmongering in past decades to effusive optimism today. Public discourse about the risks and benefits of psychedelics can and should instead be grounded in the growing evidence from clinical trials as well as participant reports. While most adverse events related to pyschedelics are mild, some have been severe and serious, and public education about the existence and nature of those risks is necessary. We predict that as more studies are conducted and eligibility criteria are relaxed to improve access, the incidence and severity of adverse events will increase. While no medical intervention is risk-free, it will be increasingly important to quantify and effectively communicate the risk/benefit profile of psychedelics.
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 59-62
Adverse Events Should Not Be Surprising in Psychedelic Research
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics within the scientific community and broader public. Coverage of psychedelic science has swung between a pendulum of extremes, from fearmongering in past decades to effusive optimism today. Public discourse about the risks and benefits of psychedelics can and should instead be grounded in the growing evidence from clinical trials as well as participant reports. While most adverse events related to pyschedelics are mild, some have been severe and serious, and public education about the existence and nature of those risks is necessary. We predict that as more studies are conducted and eligibility criteria are relaxed to improve access, the incidence and severity of adverse events will increase. While no medical intervention is risk-free, it will be increasingly important to quantify and effectively communicate the risk/benefit profile of psychedelics.
- Open Access
- 16 April 2024
- Published by MDPI AG in Psychoactives
- Vol. 3 (2) , 215-234
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted from the overstatement of the risks of psychedelics to overly positive hype. As the empirical evidence is more equivocal than frequently portrayed, the conclusions about the effectiveness of psychedelics should be considered preliminary. Poor science communication about psychedelics’ therapeutic potential may lead potential participants or patients to feel misled and policy decisions to be misinformed. An evidence-informed characterization of their risks and benefits is needed. Objectives: This article assesses the state of psychedelic research for treating depression and the effect sizes of psychedelics on therapeutic outcomes, the risk of bias, and the prevalence of adverse effects. We review research on the risks and benefits of psychedelics and discuss how the following depression treatments have shown decreasing effect sizes over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, and (4) ketamine. We speculate that a similar trend may occur for psychedelic treatments. Results and conclusions: It is likely that larger and better-controlled psychedelic trials will demonstrate smaller effect sizes that are more comparable to other conventional and emerging treatments for mood disorders. Clear science communication is critical for setting public expectations and psychedelic policy. With this evidence-based assessment, we aim to cut through the misinformation about the benefits, risks, and future prospects of psychedelic treatments.
- 16 April 2024
- Published by MDPI AG in Psychoactives
- Vol. 3 (2) , 215-234
Open AccessMind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted from the overstatement of the risks of psychedelics to overly positive hype. As the empirical evidence is more equivocal than frequently portrayed, the conclusions about the effectiveness of psychedelics should be considered preliminary. Poor science communication about psychedelics’ therapeutic potential may lead potential participants or patients to feel misled and policy decisions to be misinformed. An evidence-informed characterization of their risks and benefits is needed. Objectives: This article assesses the state of psychedelic research for treating depression and the effect sizes of psychedelics on therapeutic outcomes, the risk of bias, and the prevalence of adverse effects. We review research on the risks and benefits of psychedelics and discuss how the following depression treatments have shown decreasing effect sizes over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, and (4) ketamine. We speculate that a similar trend may occur for psychedelic treatments. Results and conclusions: It is likely that larger and better-controlled psychedelic trials will demonstrate smaller effect sizes that are more comparable to other conventional and emerging treatments for mood disorders. Clear science communication is critical for setting public expectations and psychedelic policy. With this evidence-based assessment, we aim to cut through the misinformation about the benefits, risks, and future prospects of psychedelic treatments.
- Open Access
- 1 March 2024
- Published by Elsevier in Experimental Gerontology
- Vol. 188, 112388
Fatigue and perceived energy in a sample of older adults over 10 years: A resting state functional connectivity study of neural correlates
- 1 March 2024
- Published by Elsevier in Experimental Gerontology
- Vol. 188, 112388
Open AccessFatigue and perceived energy in a sample of older adults over 10 years: A resting state functional connectivity study of neural correlates
- 29 September 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 78 (12) , 2407-2414
Longitudinal Associations Between Higher Self-Reported Energy, Gait Speed, and Cognition in Older Adults With Fatigue
Background: Older adults reporting higher energy levels have better physical function. It is not known if these associations persist among older adults reporting fatigue or if higher energy is associated with cognitive function. We examined longitudinal associations between self-reported energy, gait speed, and cognition, stratified by fatigue, in 2 613 participants (aged 74.6 ± 2.87 years) in the Health, Aging and Body Composition Study. Methods: Self-reported energy (0–10, dichotomized at median) and fatigue (present/absent) were measured at baseline. Usual and rapid-paced gait speed (m/s), modified Mini-Mental State Examination (3MS), and Digit Symbol Substitution Test (DSST) were measured at baseline and annually over 8 years. Linear mixed effect models compared changes in gait speed, 3MS, and DSST between higher and lower energy groups within fatigue strata. Results: At baseline, 724 participants (27%) were fatigued; 240 (33%) coreported higher energy (9% of total). The remaining 1 889 participants were fatigue-free (73%); 1 221 (65%) coreported higher energy (47% of total). Those with fatigue and higher energy had average rapid gait declines of 0.007 m/s per year (p = .04) after adjustment for demographics, comorbidities, depressive symptoms, and exercise. DSST declines were found among only fatigue-free participants (β = 0.17, p = .01). No statistically significant associations with energy were found for fatigue-free participants, or for usual gait or 3MS. Conclusions: Asking about older adults’ energy levels as well as fatigue may identify a subgroup of older adults protected against physical and cognitive decline, even among those with fatigue.
- 29 September 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 78 (12) , 2407-2414
Longitudinal Associations Between Higher Self-Reported Energy, Gait Speed, and Cognition in Older Adults With Fatigue
Background: Older adults reporting higher energy levels have better physical function. It is not known if these associations persist among older adults reporting fatigue or if higher energy is associated with cognitive function. We examined longitudinal associations between self-reported energy, gait speed, and cognition, stratified by fatigue, in 2 613 participants (aged 74.6 ± 2.87 years) in the Health, Aging and Body Composition Study. Methods: Self-reported energy (0–10, dichotomized at median) and fatigue (present/absent) were measured at baseline. Usual and rapid-paced gait speed (m/s), modified Mini-Mental State Examination (3MS), and Digit Symbol Substitution Test (DSST) were measured at baseline and annually over 8 years. Linear mixed effect models compared changes in gait speed, 3MS, and DSST between higher and lower energy groups within fatigue strata. Results: At baseline, 724 participants (27%) were fatigued; 240 (33%) coreported higher energy (9% of total). The remaining 1 889 participants were fatigue-free (73%); 1 221 (65%) coreported higher energy (47% of total). Those with fatigue and higher energy had average rapid gait declines of 0.007 m/s per year (p = .04) after adjustment for demographics, comorbidities, depressive symptoms, and exercise. DSST declines were found among only fatigue-free participants (β = 0.17, p = .01). No statistically significant associations with energy were found for fatigue-free participants, or for usual gait or 3MS. Conclusions: Asking about older adults’ energy levels as well as fatigue may identify a subgroup of older adults protected against physical and cognitive decline, even among those with fatigue.
- 23 July 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (11) , 3134-3141
Declining energy predicts incident mobility disability and mortality risk in healthy older adults
Background: The purpose was to examine whether longitudinal changes in self‐reported energy predict incident mobility disability and mortality. We further explored whether changes in energy‐related behaviors (physical activity, appetite, or sleep quality) would explain these associations. Methods: N = 2021 participants from the Health, Aging and Body Composition Study free from mobility disability and with at least three energy assessments from years 2 to 10. Measurements: The outcomes were time to first self‐reported inability to walk a quarter of a mile (mobility disability) and death. Self‐reported energy level (SEL) was a single‐item indicator over the prior month, ranging from 0 to 10; person‐specific slopes measured whether individuals increased or decreased in SEL across the total follow‐up time (mean 7.09 years, +1.72, range 2–8 years). Potential energy‐related mediators were baseline and change in self‐reported physical activity, appetite, and sleep quality. Covariates were baseline levels and change in demographics, health characteristics and behaviors, tiredness, cognition, mood, and gait speed. Results: A total of 947 developed disability and 567 died over the study follow‐up. A one‐point change in SEL over the follow‐up (or an average 0.125 points/year) was inversely associated with a 35% risk of incident mobility disability (hazard ratio = 0.65, 95% confidence interval [CI] = 0.55, 0.76, p < 0.001) and 33% risk of death (hazard ratio = 0.67, 95% CI = 0.42, 0.87, p = 0.003), independent of covariates. Potential energy‐related mediators did not attenuate this association. Conclusions: In this longitudinal analysis of community‐dwelling older adults, energy decline was common and a significant independent predictor of disability risk and mortality.
- 23 July 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (11) , 3134-3141
Declining energy predicts incident mobility disability and mortality risk in healthy older adults
Background: The purpose was to examine whether longitudinal changes in self‐reported energy predict incident mobility disability and mortality. We further explored whether changes in energy‐related behaviors (physical activity, appetite, or sleep quality) would explain these associations. Methods: N = 2021 participants from the Health, Aging and Body Composition Study free from mobility disability and with at least three energy assessments from years 2 to 10. Measurements: The outcomes were time to first self‐reported inability to walk a quarter of a mile (mobility disability) and death. Self‐reported energy level (SEL) was a single‐item indicator over the prior month, ranging from 0 to 10; person‐specific slopes measured whether individuals increased or decreased in SEL across the total follow‐up time (mean 7.09 years, +1.72, range 2–8 years). Potential energy‐related mediators were baseline and change in self‐reported physical activity, appetite, and sleep quality. Covariates were baseline levels and change in demographics, health characteristics and behaviors, tiredness, cognition, mood, and gait speed. Results: A total of 947 developed disability and 567 died over the study follow‐up. A one‐point change in SEL over the follow‐up (or an average 0.125 points/year) was inversely associated with a 35% risk of incident mobility disability (hazard ratio = 0.65, 95% confidence interval [CI] = 0.55, 0.76, p < 0.001) and 33% risk of death (hazard ratio = 0.67, 95% CI = 0.42, 0.87, p = 0.003), independent of covariates. Potential energy‐related mediators did not attenuate this association. Conclusions: In this longitudinal analysis of community‐dwelling older adults, energy decline was common and a significant independent predictor of disability risk and mortality.